Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report
Frontiers in Oncology · 04.05.2026 · 16
DOI: 10.3389/fonc.2026.1652716 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.05.2026. Verfasst von Ruiyue Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HER2-low breast cancer, defined as immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization (ISH), has emerged as a clinically relevant therapeutic subgroup. We report the case of a 40-year-old woman with heavily pretreated HER2-low metastatic breast cancer who received disitamab vedotin (RC-48) after failure of multiple prior systemic therapies. During the disease course, HER2 status changed dynamically from HER2-low at initial diagnosis to HER2–0 after metastasis, and then to HER2-low again after further progression, highlighting the biological heterogeneity of metastatic breast cancer and the importance of repeat biopsy. Following RC-48 treatment, chest-wall cutaneous lesions regressed markedly, tumor markers showed partial biochemical improvement, and imaging demonstrated substantial shrinkage of visceral metastatic lesions. The time to treatment failure (TTF) was 4.6 months. After treatment discontinuation following a COVID-19-associated septic shock event, the patient declined further anticancer therapy and subsequently died 13.7 months after RC-48 initiation. Therefore, survival outcomes should be interpreted cautiously. As the first China-developed anti-HER2 antibody-drug conjugate (ADC), RC-48 may provide clinically meaningful benefit in selected patients with HER2-low metastatic breast cancer. This case also underscores the importance of reassessing HER2 status during disease evolution and supports the potential value of ADC-based therapy in later-line treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
- Breast Tumor Center, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Zitieren
APA
Wu, R., Chen, X., Li, T., Zhang, Y., & Ling, X. (2026). Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1652716
Vancouver
Wu R, Chen X, Li T, Zhang Y, Ling X. Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1652716
BibTeX
@article{Wu2026,
author = {Wu, Ruiyue and Chen, Xi and Li, Tong and Zhang, Yunmei and Ling, Xiaoling},
title = {Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1652716}
}
EUVIMED